22.05.2017 Views

Review of Pharmacology - 9E (2015)

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

General <strong>Pharmacology</strong><br />

6. Ans. (b) b (Beta) receptor (Ref: KDT 7/e p46)<br />

7. Ans. (b) Sequestered in tissues (Ref: KDT 7/e p18)<br />

8. Ans. (b) Single compound (Ref: KDT 7/e p4)<br />

9. Ans. (c) Corticosteroids (Ref: KDT 7/e p66)<br />

10. Ans. (b) Post marketing surveillance (Ref: KDT 7/e p80)<br />

11. Ans. (b) Enzyme inhibitor (Ref: Goodman Gilman 12/e p139)<br />

• Grapefruit juice contains furano cumarins and naringin that are cyp 3A4 inhibitors.<br />

12. Ans. (b) Prostacycline-Thromboxane (Ref: KDT 7/e p58)<br />

13. Ans. (b) Neostigmine (Ref: KDT 7/e p105)<br />

14. Ans. (c) Safety (Ref: KDT 7/e p56)<br />

15. Ans. (b) Schedule H (Ref: KDT 7/e p5)<br />

16. Ans. (d) Metoclopramide (Ref: KDT 7/e p89)<br />

17. Ans. (b) Insulin (Ref: KDT 7/e p49)<br />

• Nicotine acts on N M<br />

and N N<br />

receptors which are inotropic receptors.<br />

• Diazepam acts on GABA-BZD-CL channel complex that mediates entry <strong>of</strong> chloride.<br />

• Glibenclamide is a sulforylurea that acts on ACh sensitive K + channels.<br />

• Insulin acts on enzymatic receptors.<br />

18. Ans. (d) Maximum response a drug can produce (Ref: KDT 7/e p54)<br />

19. Ans. (a) Defect in development <strong>of</strong> long bones (Ref: KDT 7/e p89)<br />

20. Ans. (c) Drug toxicity (Ref: KDT 7/e p80)<br />

21. Ans. (a) Hydralazine (Ref: KDT 7/e p66)<br />

22. Ans. (b) Rifampicin (Ref: KDT 7/e p326)<br />

23. Ans. (c) Inverse agonist (Ref: KDT 7/e p42)<br />

24. Ans. (a) Pharmacogenomics (Ref: KDT 7/e p65)<br />

25. Ans. (d) Alcohol and theophylline (Ref: KDT 7/e p31)<br />

26. Ans. (d) Body surface area (Ref: KDT 7/e p63)<br />

27. Ans. (b) Metformin (Ref: KDT 7/e p34)<br />

28. Ans. (a) Cimetidine (Ref: KDT 7/e p26)<br />

29. Ans. (c) Corrosive acid poisoning (Ref: KDT 7/e p85)<br />

30. Ans. (b) Nitrate induced headache (Ref: KDT 7/e p86)<br />

31. Ans. (b) After a drug is marketed (Ref: KDT 7/e p80)<br />

32. Ans. (a) Phenobarbitone (Ref: KDT 7/e p29)<br />

33. Ans. (a) Propylthiouracil (Ref: KDT 7/e p89)<br />

34. Ans. (c) Agonists and antagonists bind to the same receptor (Ref: KDT 7/e p39)<br />

35. Ans. (b) Transdermal (Ref: KDT 7/e p6)<br />

36. Ans. (c) That satisfy the priority health care needs <strong>of</strong> the population (Ref: KDT 7/e p4)<br />

37. Ans. (a) Competitive inhibitor (Ref: KDT 7/e p39)<br />

38. Ans. (a) Phase I <strong>of</strong> clinical trial (Ref: KDT 7/e p63)<br />

39. Ans. (d) Drugs for rare disease (Ref: KDT 7/e p5)<br />

40. Ans. (d) Digoxin poisoning (Ref: KDT 7/e p18)<br />

General <strong>Pharmacology</strong><br />

53<br />

https://kat.cr/user/Blink99/

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!